Amneal Pharmaceuticals stock gains after FDA approval for lanreotide injection

Amneal Pharmaceuticals, Inc. stock (ISIN US03168L1052) advanced after the company announced U.S. Food and Drug Administration approval for its lanreotide injection and launched the generic hormone therapy immediately in the United States on September 18, 2026. According to The Manila Times on September 18, 2026, the FDA approved Amneal's lanreotide injection referencing Somatuline Depot and the company began marketing the product right away in a market with branded sales of USD 983 million in the 12 months to July 2026.

FDA approval and launch of generic lanreotide

As Simply Wall St reported on September 19, 2026, Amneal received FDA approval for its lanreotide injection 120 mg/0.5 mL in a sterile, single dose prefilled syringe referencing Somatuline Depot and secured Competitive Generic Therapy designation, with a U.S. launch in a market where the branded product generated USD 983 million in sales in the 12 months to July 2026. The therapy is used for conditions such as acromegaly, giving Amneal a foothold in a high-value endocrine segment where the originator drug has dominated until now.

According to RTTNews on September 18, 2026, Amneal said the FDA approval allows immediate commercialization of its lanreotide injection as a generic alternative to Somatuline Depot, and management highlighted the Competitive Generic Therapy status as a potential driver of favorable market access and pricing. For investors, the combination of a large reference market near USD 1.0 billion and the generic's designation creates a concrete growth option that can complement the existing portfolio of generics and specialty pharmaceuticals.

Stock reaction, valuation and market metrics

Per MSN on September 18, 2026, Amneal Pharmaceuticals shares closed that trading day at USD 18.71 on Nasdaq, up 2.35 percent from the prior close, and then gained a further 2 percent in after-hours trading to USD 19.17 as investors digested the FDA approval and immediate launch. The same report noted that AMRX stock has risen 48 percent year-to-date, underscoring how strongly the market has re-rated the company ahead of and around the hormone therapy catalyst.

According to stock portal WallStreetZen as of September 18, 2026, Amneal Pharmaceuticals stock traded at USD 18.71 per share on Nasdaq, while the platform estimated a discounted cash flow based fair value of USD 9.92 per share, meaning the market price stood 88.53 percent above that fair value estimate. The same overview shows Amneal's market capitalization at USD 5.98 billion as of September 19, 2026, highlighting how the company has joined the mid-cap tier within the U.S. generics and specialty pharmaceutical universe.

Valuation metrics underline the stretched pricing: WallStreetZen reports a price-to-earnings ratio of 37.42 and a price-to-book ratio of 180.93 for Amneal as of September 18, 2026, both well above typical levels for mature generics companies. For investors, the key question is whether the earnings contribution from the newly launched lanreotide injection and other growth drivers can justify a share price that one fair value model sees nearly 90 percent above intrinsic value.

Growth opportunity versus execution risk

According to GuruFocus on September 18, 2026, Amneal Pharmaceuticals shares at USD 18.71 were 128.4 percent above the platform's proprietary GF Value estimate of USD 8.19 per share, suggesting the stock is significantly overvalued with a thin margin of safety for new investors. The analysis emphasizes that the market price reflects high expectations for future growth, including contributions from the lanreotide generic, and cautions that any disappointment in uptake or pricing could weigh on returns.

The same GuruFocus piece notes that, while Amneal has improved its growth and momentum scores, the valuation component grades the stock weak due to the large premium over estimated intrinsic value. For investors, that quantified gap of 128.4 percent between market price and GF Value highlights the execution risk around the lanreotide launch and other pipeline initiatives: revenue must ramp meaningfully in a USD 983 million reference market to support current multiples.

At the same time, WallStreetZen assigns Amneal a composite rating with stronger grades for growth and momentum than for value and safety, reflecting its profile as a company in transition after several years of balance sheet repair and portfolio reshaping. In practical terms, that means the market is willing to pay up for exposure to specific growth catalysts such as the hormone therapy generic, but is also signaling that the stock is more suitable for investors comfortable with elevated volatility and valuation risk.

Stock level and investor perspective

On Nasdaq, Amneal Pharmaceuticals stock most recently closed at USD 18.71 on September 18, 2026, in regular trading, before moving higher in post-market dealing on the same day. With a year-to-date increase of 48 percent and fair value models from WallStreetZen and GuruFocus placing the intrinsic value between USD 8.19 and USD 9.92 per share, the current market level leaves limited room for further rerating without a clear acceleration in reported earnings.

More news and analyses on Amneal Pharmaceuticals stock